Keyhole limpet haemocyanin – a model antigen for human immunotoxicological studies by Swaminathan, Ashwin et al.
1 
This article is protected by copyright. All rights reserved.
Title Page 
Keyhole limpet haemocyanin - a model antigen for human 
immunotoxicological studies1 
Authors: 
Dr Ashwin Swaminathan MBBS PhD; Research Fellow1, Physician2 
Professor Robyn M Lucas MBChB PhD 1,3 
Professor Keith Dear PhD 4 
Professor Anthony J McMichael MBBS PhD1 
1. National Centre for Epidemiology and Population Health, Australian National University,
Canberra, Australia 
2. Infectious Diseases and General Medicine Units, Canberra Hospital, Canberra, Australia
3. Telethon Kids Institute, University of Western Australia, Perth, Australia
4. Duke Global Health Institute, Duke Kunshan University, Kunshan, Jiangsu, China
Corresponding Author 
Dr Ashwin Swaminathan 
National Centre for Epidemiology and Population Health 
Australian National University 
Corner Eggleston and Mills Rds, ANU 
Canberra ACT 0200 
                        
This article has been accepted for publication and undergone full peer review but has not been through the 
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this 
version and the Version of Record. Please cite this article as doi: 10.1111/bcp.12422 
A
cc
ep
te
d 
A
rti
cl
e
"This is the peer reviewed version of the following article: Swaminathan, A., Lucas, R. M., Dear, K. and McMichael, A. J. 
(2014), Keyhole limpet haemocyanin – a model antigen for human immunotoxicological studies. British Journal of 
Clinical Pharmacology, 78: 1135–1142. doi: 10.1111/bcp.12422 which has been published in final form at 10.1111/
bcp.12422.  This article may be used for non-commercial purposes in accordance with Wiley terms and conditions for 
self-archiving"
2 
This article is protected by copyright. All rights reserved. 
E: Ashwin.swaminathan@anu.edu.au 
T: + 61 402 864 812 
Summary 
Immunisation with a T-cell dependent antigen has been promoted as a reliable and sensitive tool for 
assessing the influence of putative immunotoxic exposures or agents on immune function.  Keyhole 
limpet haemocyanin (KLH) is a very large, copper-containing protein molecule derived from the 
haemolymph of the inedible mollusc, Megathura crenulata. KLH is a highly immunogenic T-cell 
dependent antigen that is used increasingly in immunotoxicological studies, particularly in those 
involving animals.  This report systematically reviews the human clinical studies that have used 
trans-cutaneous KLH immunisation for assessment of the influence of various physiological and 
disease states and exposures on immune function over the last twenty years (1994 – 2013). These 
studies varied in their immunisation protocols, formulation of KLH, dose, site and route of 
administration and immunoassay platforms developed to assess KLH-specific responses. KLH 
immunisation has been well tolerated with only mild to moderate adverse effects reported.   Though 
very promising as a model antigen candidate in immunotoxicology research, more work on 
standardising immunisation and immunoassay protocols is required.
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Introduction 
The effect of extrinsic (e.g. environmental exposure) or intrinsic (e.g. psychological distress) factors 
on the human immune system can be effectively assessed by quantifying the antigen-specific 
response to immunisation with a T-cell dependent antigen, although care needs to be taken with the 
choice of antigen (1,2).  Keyhole limpet haemocyanin (KLH) is an immunogenic protein antigen that 
is xenogeneic to the mammalian immune system.   It is used primarily in animal immunotoxicological 
studies but has a number of applications in the human context including as a vaccine conjugate 
peptide and in immunotherapy. However, practical aspects regarding the utility of KLH as a 
diagnostic antigen in human immunotoxicology studies have not previously been reviewed in detail.  
This paper describes the ideal attributes of a vaccine candidate for human immunotoxicology studies 
and the structure and immunostimulatory properties of KLH.  We then present a systematic review 
of the use of KLH immunisation via trans-cutaneous routes in human immunotoxicological studies 
over the period 1994-2013, including its safety profile and the relevant immunoassay platforms 
required to assess the immune response to immunisation.   
Use of T-cell dependent antigens in immunotoxicological studies 
Quantification of the primary antibody response to immunisation with a T-cell dependent (TD) 
antigen (e.g. sheep red blood cells, ovalbumin, KLH, tetanus toxoid, hepatitis B surface antigen) is a 
sensitive method for assessing immunocompetence (3–6).  The immune response to immunisation 
with a TD antigen is commonly referred to as a T-cell dependent antibody response (TDAR) (7).   
Immunisation with a TD antigen permits assessment of the complex primary immune response that 
involves antigen presentation, priming and collaboration of T and B lymphocytes, antibody 
production and cytokine-dependent antibody class switching (6).   A
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In animal immunotoxicological research, assessment of a TDAR using sheep erythrocytes or KLH has 
become the functional immune assay of choice (8–10).  For human immunotoxicology studies, 
opportunistic monitoring of the responses to routine childhood vaccinations (e.g. tetanus, 
diphtheria, pertussis) has been advocated (11,12).   
What makes an ideal immunisation antigen candidate for immunotoxicology studies? 
The properties of an ideal TD antigen for immunisation have been previously described (11,13,14) 
and include the following:  
i) Pure homogeneous substance available as a clinical grade product; 
ii) Harmless, if not beneficial, to the recipient; 
iii) Highly immunogenic for the entire population without any genetic restriction; 
iv) Have no cross-reacting antibody; 
v) Elicit predictable primary immune responses (without need for an adjuvant) following a 
single administration; 
vi) Produce a measurable immune response that can differentiate subtle changes in 
immunomodulation (i.e. have high sensitivity to detect change) using validated immune 
assays. 
Commercially available vaccines (e.g. hepatitis B, influenza, tetanus) have the advantages of already 
having passed strict safety regulatory processes, providing a protective benefit for study participants 
and being available in a clinical grade formulation.  The main disadvantages are that in a non-
paediatric population, many participants will have been exposed to antigen from wild-type infection 
or previous vaccination. Furthermore, commercial vaccines produce a robust immune response that 
potentially overwhelms the assay’s ability to detect subtle changes in immune response.  As A
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mentioned, KLH is often used in animal immunotoxicological research and has many of the qualities 
of an ‘ideal’ vaccine candidate (13). 
KLH: Structure, properties and biological uses 
KLH is derived from the haemolymph of the inedible marine mollusc, Megathura crenulata, native to 
the Pacific coastal waters of California and Mexico (15).  KLH is traditionally harvested from molluscs 
by lethal ex-sanguination, leading to concerns regarding the sustainable supply of research and 
commercial KLH quantities given the depletion of native marine stocks.  However, new non-lethal 
techniques for the extraction of haemolymph and sustainable aquaculture practices have lessened 
this concern (16).   
 
Hemocyanins are cylindrical, copper-containing molecules that act as oxygen-transporting proteins 
for many mollusc species.  KLH is an extremely large molecule (~8,000kDa) comprising a variable 
number of sub-units (KLH1 (390kDa) and KLH2 (350kDa)) (15,17). The remarkable 
immunostimulatory properties of KLH result from high antigenicity derived from numerous 
carbohydrate and peptide epitopes (15,18).   
 
The potent immunogenicity of KLH has been known for over 40 years (19–21) and since that time 
KLH has been used extensively in animal and human research to delineate cellular and humoral 
immune responses, as a carrier protein for cancer vaccines and as bladder cancer immunotherapy 
(22,23). KLH appears to have anti-proliferative action against certain tumour cell lines, including 
breast, pancreatic and oesophageal cancer (24,25). 
  
KLH is xenogeneic to the human immune system and therefore promotes a reliable primary immune 
response, however individuals with exposure to the fluke Schistosoma mansoni can have cross-
reactive antibodies to a shared carbohydrate epitope (18).   
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KLH immunisation as a test of immune status in humans: a systematic review 
OBJECTIVES 
KLH immunisation has been used in a number of clinical studies to assess the influence of various 
physiological and disease states and exposures on immune function.  These have included 
psychological states (26–30), cardiovascular exercise (31,32), cancer and/or chemotherapy 
(13,21,33,34), immunodeficiency states (35–37), atopy and asthma(38,39) and autoimmune 
disease(40,41).  Our objectives in this systematic review were to: i. Survey the formulations, modes 
of administration and doses used; ii. Assess the available safety data; and iii. Summarise the 
measures of antigen-specific immune response used, both antibody- and cell-mediated. 
 
METHODS 
We identified studies conducted over the last 20 years where a trans-cutaneous KLH immunisation 
route was used for the purpose of assessing immune function and where KLH-specific immune 
parameters were the primary or secondary immunological end-points.  Studies were identified from 
PubMed, US Library of Medicine (http://www.ncbi.nlm.nih.gov/pubmed) using the following 
parameters – Keywords: “KLH” or “keyhole limpet”; Time period: 1 January 1994 to 31 December 
2013;  Language: English.  Only studies with online abstracts available were screened for possible 
inclusion in this review. Table 1 details the sixteen human clinical trials found. 
 
[See Table 1] 
 
RESULTS 
1.  Formulation, administration and dose A
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KLH for clinical use comes in two forms – high molecular weight (HMW) and sub-unit preparations.  
Both preparations are available in a clinical grade formulation that is sterile and endotoxin and 
pyrogen free.  Sub-unit KLH (~400kDa) is often used as a vaccine carrier protein that is coupled to a 
carbohydrate or other non-immunogenic molecule to boost T-cell priming (e.g. novel anti-cancer 
vaccines (46)).  HMW KLH (or ‘native’ KLH) preserves the weight of the larger molecule, although 
manufacturers have found quality control issues to be more challenging (47). 
HMW-KLH has greater immunogenicity compared with sub-unit KLH, as demonstrated in the study 
conducted by Miller et al (33).  Here, three forms of 1000µg KLH were administered to healthy 
participants: HMW KLH, sub-unit KLH or sub-unit KLH with mineral oil adjuvant (Montanide ISA-51). 
A similar and potent immune response was seen in participants immunised with the HMW-KLH and 
sub-unit KLH with adjuvant, but not in those immunised with sub-unit KLH alone.  It was postulated 
that the lack of response was not due to a lack of important immunogenic epitopes in sub-unit-KLH 
but, instead, was due to an adjuvant property of HMW KLH that was successfully substituted by use 
of the mineral oil adjuvant.    
A measureable, robust antigen-specific immune response can be generated following administration 
of KLH via a number of routes – intra-dermal (35,37,40), sub-cutaneous (33,36,43–45), intra-
muscular (28,30–32,38,42) and inhalational (39).  Studies that administered KLH intra-muscularly 
used the deltoid muscle.  Site of sub-cutaneous administration was documented over the deltoid 
(44) or “arm” (45), whilst intra-dermal immunisation was given in the upper arm (35) or forearm 
(40). In those studies assessing DTH response, intra-dermal KLH was administered to the volar aspect 
of the forearm (29), upper arm (13) or gluteal aspect of the leg (44). 
Older studies have used immunisation doses of KLH up to 5000µg (21), although the range in the 
recent clinical studies reviewed was 8 µg to 1000 µg, with 100 µg being the most frequent dose.  
Only one study reviewed was unable to detect a quantifiable antibody response post-immunisation 
(34), which was likely attributable to the immunosuppressed state of the study population.   In the A
cc
ep
te
d 
A
rti
cl
e
8 
This article is protected by copyright. All rights reserved. 
only published study to assess the effect of different doses of the same KLH formulation, Curtis et al 
(21) reported no significant difference in the kinetics or magnitude of the immune response amongst 
participants immunised with 10µg, 100µg or 5000µg of HMW KLH.  
2. Safety profile 
KLH has an excellent clinical safety profile, as noted by several authors (23,29).  In their 
comprehensive review, Harris & Markl (15) state, “Importantly, KLH is considered to be an extremely 
safe substance for in vivo use in man, as a direct antigenic stimulus and immunotherapeutic agent” 
(pp. 614).  KLH immunotherapy for bladder cancer has received European regulatory approval  (48).  
There was no report of significant adverse events related to the use of KLH in any human clinical 
study reviewed for this paper.  Reports of mild adverse effects (e.g. itching, rash, soreness at 
injection site and malaise) attributable to KLH vaccination occurred in 9 of 103 participants in one 
clinical trial (36). Importantly, potential adverse effects increase if vaccine adjuvants are used in 
conjunction with KLH (e.g. alum, oil-water adjuvants or mineral-oil adjuvants)(49,50).  
 
Despite the excellent safety profile of KLH in clinical studies, most studies have excluded patients 
with a history of shellfish allergy.  There have been reports of anaphylaxis following ingestion of a 
related mollusc species, the grand keyhole limpet (GKL), with cross-antigenicity between GKL, 
abalone and KLH demonstrated (51). 
 
3. Measures of antigen-specific immune response 
Quantifying the KLH-specific antibody response 
Most studies that have used KLH immunisation to assess an antigen-specific immune response have 
measured KLH antibodies (14 of the 16 unique studies listed in Table 1), with most studies utilising 
indirect ELISA assays.  A multiplex flow cytometric bead array platform has been recently reported 
that allows a semi-quantitative assessment of multiple antibody targets simultaneously, an advance 
on previous single-plex ELISA platforms (40).   Studies have differed by the timing of serum sampling, A
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immunoglobulin sub-type targets (e.g. IgM, IgG and/or IgG sub-sets) and how the result was 
analysed and reported.  There were also differences in the reagents and protocols used for the 
assays.   
 
Table 2 summarises the timing of serum sampling from participants relative to KLH immunisation for 
the fourteen relevant studies from Table 1.  All studies tested KLH antibodies at baseline, then at 
variable time-points after immunisation, with sampling at Weeks 2 (71%), 4 (43%) and 3 (36%), 
respectively, the next most frequent. KLH IgG (or an IgG sub-set) was assayed in 14 (100%), IgM in 10 
(71%), IgE in 2 (14%) and IgA in 1 (7%) of the studies that measured antibodies.   
 
[Insert Table 2] 
 
Studies have also differed in how the KLH antibody titre was read and presented.  For example,  
standard curves have been generated using sera with known concentrations of KLH antibody, and 
against these the concentration of anti-KLH antibodies in subjects’ samples were interpolated 
(33,35,38).  Other studies have compared the optical density (measure of colour change/light 
absorbance in wells) of sample sera at defined dilutions with the positive and negative control sera 
on the same plate which also allowed adjustment for inter-plate variation in absorbance readings 
(28,31,32).  One study assayed KLH IgG and IgM at three dilutions (not specified) and calculated the 
average across dilutions for analyses (30).   
 
Quantifying the cell-mediated immunity response  
Many of the studies reviewed assessed aspects of cell-mediated immunity ex vivo following KLH 
immunisation (28,33,35,37,38,40,42,43,45).  The majority of these studies used conventional 
lymphocyte proliferation assays, with the main difference between them being the incubation A
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periods of the peripheral blood mononuclear cells (PBMCs) with KLH, ranging from 5 days (28) to 7 
days (33).   
Cytokine production by stimulated PBMCs following KLH immunisation was assessed in two recent 
studies. Interferon-γ (IFN- γ ) production was determined by ELISPOT assay after thawed PBMCs 
were incubated with KLH for 20 hours (33). Spazierer et al (38) incubated cells with KLH for 40 hours 
then tested the supernatant for IL-4, IL-5, IL-10, IL-13 and IFN-γ using antibody-coated magnetic 
bead assays.   
Ferbas et al (40) developed a B-lymphocyte ELISPOT that could enumerate antigen-specific B cells 
secreting KLH IgG at various time-points post-immunisation, thereby showing the kinetics of the 
cellular response and the relationship with serum KLH IgG levels.  In an innovative study, Kantele et 
al (43) sorted peripheral blood lymphocyte cell populations by their tissue-specific homing receptors 
(e.g. L-selectin for lymph node tissue; α4β7 for intestine), then utilised ELISPOT assays to identify 
which of these cells secreted KLH-specific antibody.  This research showed that the immune 
response following KLH immunisation was characterised by a non-intestinal, systemic homing 
profile. 
Delayed-type hypersensitivity (DTH) testing is a validated in vivo test of antigen-specific cell-
mediated immunity. A number of the reviewed clinical studies used DTH tests to assess in vivo KLH-
specific cell-mediated immunity (28,31,32,37,42,44,45).  The studies have varied in the initial 
immunisation KLH dose, as well as formulation and subsequent skin test dose (see Table 1).   
There are conflicting data regarding the minimum sensitising and subsequent skin test dose required 
to induce a reliable DTH response.  Grant et al (32) were unable to elicit a DTH response after 
administration of a 5µg intra-dermal skin test dose three weeks following immunisation with 125µg 
HMW KLH administered intra-muscularly.  Contrasting with this finding, a very early study found that 
the DTH response was independent of initial sensitising immunisation dose (i.e. 5000µg / 100µg / A
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1µg were equivalent) (21).  However, higher subsequent skin test dose yielded a higher proportion 
and magnitude of positive DTH responses in a dose dependent manner (i.e. 100µg > 10µg > 1µg ) 
(21).  Skin testing with simultaneous doses of 0.1, 1 and 10µg KLH at day 7 and day 14 post-
immunisation (with 200µg HMW KLH) achieved a DTH response rate of 68% amongst healthy control 
participants (although the results at each skin test dose were not provided) (13).  
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Conclusions 
KLH is a potent immunostimulatory antigen that has been used in a number of human clinical 
research settings and has an excellent safety profile.  A robust immune response can be attained 
from immunisation with a single dose of KLH by various routes and in various doses.  Sub-unit KLH 
needs to be combined with an adjuvant to match the immunogenicity of HMW KLH.  There is 
currently no uniform sampling time/s or laboratory platform for measuring the humoral or cellular 
KLH-specific response following immunisation.  Development of a standardised approach to KLH 
administration and measurement of antigen specific immune outcomes is required to increase the 
utility of this very promising agent in human immunotoxicology studies. 
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Table 1: Clinical studies using keyhole limpet haemocyanin (KLH) administered via a trans-cutaneous route to assess the influence of an exposure or 
agent on immune response in humans (Studies conducted between 1994 – 2013) 
Study and aim KLH formulation (Source), dose, 
route & site of administration 
Antibody assessment: assay type, 
target immunoglobulin(s), sampling 
period relative to immunisation 
Cell-mediated immunity (Ex vivo and in 
vivo testing) 
Ferbas et al (2013)(40) 
To assess performance characteristics of  
immunoassays measuring antigen 
specific response to KLH immunisation 
in healthy controls and patients with 
systemic lupus erythematosus 
HMW-KLH (ImmuneActivator
TM
, 
Intracel, Rockville, USA) 
1000µg  
ID 
Forearm 
2 doses: Day 1 & 29 
Flow cytometric bead array 
KLH IgM and IgG; IgG1-4 
Baseline and days 7, 14, 28, 35 and 42 
post-immunisation 
 
Ex vivo: ELISPOT assay to detect 
numbers of B cells secreting KLH IgG  
In vivo: Not evaluated 
Gallegos et al (2013)(30) 
To examine the effects of mindfulness-
based stress reduction on 
immunological outcomes in older adults 
KLH formulation not noted 
8, 40, 100, 200, 1000µg KLH 
IM 
Deltoid muscle 
ELISA (type not-specified) 
KLH IgM and IgG 
Baseline, 3 & 24 weeks post 
immunisation 
Not evaluated 
Boulton et al (2012)(42) 
To examine the influence of fingolimod 
therapy on immune responses to 
immunisation with neo-antigens and 
recall antigens 
Sub-unit KLH (Immucothel
®
, Biosyn, 
Carlsbad, USA) 
0.5mL(100µg) adsorbed to alum 
IM 
Site not specified 
 
 
 
Indirect ELISA 
KLH IgM, IgG 
Baseline and 1, 2, 3, 5 and 7 weeks post-
immunisation 
Ex vivo: Not evaluated 
 
In vivo: 10µg KLH ID X-weeks post-
immunisation; Anterior aspect of upper 
or lower arm; Read at 48 hours 
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Kantele et al (2011)(43) 
To examine the tissue homing response 
of lymphocytes following KLH 
immunisation and secretion of KLH 
antibodies at a cellular level  
HMW-KLH (Pacific Biomarine, 
Venice, USA) 
100 µg  
SC 
Site not specified 
Quantification of serum KLH antibodies 
not performed 
Ex vivo: ELISPOT assay to detect number 
of B cells secreting KLH IgG, IgA and IgM 
after immune-magnetic sorting of 
lymphocytes by tissue-specific homing 
receptors  
In vivo: Not evaluated 
Bingham et al (2010)(36) 
To examine immunisation responses in 
patients with rheumatoid arthritis 
treated with rituximab 
HMW-KLH (Intracel, Frederick, 
USA) 
Dose not specified 
SC 
Site not specified 
ELISA (type not-specified) 
KLH IgG 
Baseline and 4 weeks post-immunisation 
Not evaluated 
Spazierer et al (2009) (38) 
To establish an immunisation protocol 
to induce de novo Th2 responses using 
immunisation with KLH 
 
Sub-unit KLH (Immucothel
®
, Biosyn 
Arzneimittel GmbH, Fellbach, 
Germany) 
100µg KLH with alum (dose not 
specified)  
IM  
Site not specified;  
3 doses: Day 1, 15 & 29 
Indirect and sandwich ELISA 
KLH IgG1, IgG4, IgE, IgM 
Baseline and days 14, 28, 42 & 56 post-
immunisation 
Ex vivo: Lymphocyte proliferation assays 
 
In vivo: Not evaluated 
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Grant et al (2008)
 
(32) 
To examine the effect of aerobic 
exercise in sedentary older adults on 
primary immune response to KLH 
immunisation 
HMW-KLH (BCI-
ImmuneActivator
TM
, Intracel, 
Rockville, USA) 
125µg 
IM 
Deltoid muscle 
Indirect ELISA 
KLH IgG1, IgG2, IgM 
Baseline and 2, 3 and 6 weeks post-
immunisation 
Ex vivo: Not evaluated 
In vivo: 5µg KLH ID 3-weeks post-
immunisation; Timing of reading not 
specified; Site not specified 
Miller et al (2005) (33) 
To compare the responses to KLH 
immunisation in healthy adults with  
those in immunosuppressed patients 
(cancer & bone marrow transplant 
recipients) 
HMW KLH HMW KLH (Intracel, 
Rockville, USA)    Sub-unit (Biosyn 
Corp, Carlsbad, USA) 
1. Sub-unit KLH 1000 µg  
2. HMW-KLH 1000µg  
3. Sub-unit KLH 1000µg with 
Montanide-ISA-51 adjuvant 
(0.6mL) 
SC 
Site not  specified 
Indirect & sandwich ELISA 
KLH IgG1, IgG2, IgM  
Baseline and 4 weeks post-immunisation 
Ex vivo: Lymphocyte proliferation assays; 
ELISPOT assay for cellular responses to 
KLH 
In vivo: Not evaluated 
 
 
Smith A et al (2004) (28) 
To examine the effect of distress on 
primary KLH immunisation response in 
young adults 
 
Sub-unit KLH (Pierce, Rockford, 
USA) 
100µg KLH adsorbed to 0.9mg alum  
IM   
Deltoid muscle 
 
Indirect ELISA;  
KLH IgG 
Baseline and 3 weeks post-immunisation 
Ex vivo: Lymphocyte proliferation assays 
In vivo: 1 µg ID 3 weeks post-
immunisation; Volar aspect of arm; Read 
at 48 hours 
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Smith A et al (2004) (29) 
To examine the effect  of psychological 
distress on DTH response following 
primary KLH immunisation in young 
adults 
Sub-unit KLH (Pierce, Rockford, 
USA) 
100µg KLH adsorbed to 0.9mg alum  
IM   
Deltoid muscle 
Not evaluated 
 
 
 
Ex vivo: Not evaluated 
In vivo: 1 µg ID 3 weeks post-
immunisation; Volar aspect of arm; Read 
at 48 hours 
Smith TP et al (2004) (31) 
To examine the effect of age and 
physical activity on primary immune 
response to KLH immunisation 
Sub-unit KLH (Pierce, Rockford, 
USA) 
100µg KLH adsorbed to 0.9mg alum  
IM  
Deltoid muscle 
Indirect ELISA 
KLH IgG, IgG1, IgG2 & IgM;  
Baseline and 1, 2, 3 & 4 weeks post-
immunisation 
Ex vivo: Not evaluated 
In vivo: 1 µg ID 21 days post-
immunisation; Volar aspect of arm; Read 
at 24, 48, 72, 96 & 120 hours  
Boelens PG et al (2004) (44) 
To examine the effect of severe trauma 
on early primary immune response to 
KLH immunisation in relation to low 
plasma glutathione 
 
 
KLH formulation/source not stated 
500 µg 
SC 
Deltoid region 
Indirect ELISA 
KLH IgM, IgA, IgG, IgG1-4 
Baseline and days 8 and 13 post-
immunisation 
Ex vivo:  Lymphocyte proliferation assay; 
Frequency of interferon-γ (Th1) and IL-4 
(Th2)-producing T-lymphocytes cells by 
flow cytometry assays 
In vivo:  100 µg  ID 14 days post-
immunisation; Right gluteal region of leg; 
Read at 48 hours 
Rentenaar RJ et al (2002) (45) 
To examine the cellular and humoral 
responses to immunisation in renal 
transplant recipients receiving different 
immunosuppressive regimes 
HMW KLH (Source not stated) 
1000 µg 
SC 
Right arm 
Indirect ELISA 
KLH IgG 
Baseline and day 14 post-immunisation 
Ex vivo:  Lymphocyte proliferation assay;  
In vivo:  1 & 10 µg  ID 14 days post-
immunisation; Lower arm; Read at 24 
hours 
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Van der Kolk et al (2002) (34) 
To assess the influence of rituximab on 
the humoral immune response to 
immunisation with primary and recall 
antigens in patients with low grade 
lymphoma 
HMW KLH (Calbiochem, San Diego, 
USA) 
1000 µg  
SC 
Site not specified 
Indirect ELISA 
KLH IgG 
Baseline and 14  days post-immunisation  
Not evaluated 
Valdez H et al (2000) (37) 
To assess response to immunisation 
after prolonged anti-retroviral therapy 
in patients with HIV 
HMW KLH (ImmuneActivator
TM
, 
PerImmune, Rockville, USA) 
1000 µg 
ID 
Site not stated 
Indirect ELISA 
KLH IgG 
Baseline and 2, 6, 12 and 18 weeks post-
immunisation 
Ex vivo:  Lymphocyte proliferation assays 
In vivo:  ID (dose not specified); 6 and 18 
weeks post-immunisation; Read at 48 – 
72 hours  
Kondratenko et al (1997) (35) 
To evaluate responses to primary KLH 
immunisation in patients with 
immunodeficiency states 
HMW KLH (Calbiochem, San Diego, 
USA) 
200 µg  
ID     
Upper arm 
Indirect ELISA 
KLH IgG, IgM 
Baseline and 2 & 4 weeks post-
immunisation 
Ex vivo: Lymphocyte proliferation assay 
In vivo: Not evaluated 
 
Legend:     IM: Intra-muscular; SC: sub-cutaneous; ID: Intra-dermal     HMW: High molecular weight           DTH: Delayed type hypersensitivity  
ELISPOT: Enzyme-linked immunosorbent spot assay;   
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Table 2: Timing of serum sampling for KLH antibody assays relative to KLH immunisation  
Timing of Sample    
(weeks post- 
immunisation) 
0 
(baseline) 
1 2 3 4 5 6 7 8 12 18 24 
Number of 
studies  (% of 
studies from 
Table 1*) 
14      
(100%) 
4 
(29%) 
10 
(71%) 
5 
(36%) 
6 
(43%) 
2 
(14%) 
4 
(29%) 
 
1 
(7%) 
1 
(7%) 
1 
(7%) 
1 
(7%) 
1 
(7%) 
 
* Fourteen studies from Table 1 were included here that had measured KLH specific antibodies as part of their respective study protocols 
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